<p>Aardvark Therapeutics, Inc. (NASDAQ:AARD - 獲取免費報告) 的股價在週五上漲了 12%。該股票最高交易價格為$13.03，最後交易價格為$12.65。在交易過程中，約有 152,066 股易手，較平均每日交易量 186,140 股下降了 18%。該股票之前的收盤價為$11.29。</p>
<p>獲取 <strong>Aardvark Therapeutics</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<p>AARD 已成為多份研究分析師報告的主題。Raymond James Financial 在 1 月 12 日的報告中重申了對 Aardvark Therapeutics 的 &#34;強力買入&#34; 評級，並設定了$47.00 的目標價格。B. Riley Financial 在 1 月 28 日的研究報告中開始覆蓋 Aardvark Therapeutics，並設定了 &#34;買入&#34; 評級和$32.00 的目標價格。Cantor Fitzgerald 在 11 月 14 日的報告中重新發布了對 Aardvark Therapeutics 的 &#34;增持&#34; 評級。William Blair 在 12 月 12 日的報告中開始覆蓋 Aardvark Therapeutics，併為該公司設定了 &#34;跑贏大盤&#34; 評級。最後，BTIG Research 在 11 月 7 日的研究報告中開始覆蓋 Aardvark Therapeutics，並設定了 &#34;買入&#34; 評級和$26.00 的目標價格。一位分析師給予該股票 &#34;強力買入&#34; 評級，十一位給予 &#34;買入&#34; 評級，一位給予 &#34;賣出&#34; 評級。根據 MarketBeat.com 的數據，Aardvark Therapeutics 目前的共識評級為 &#34;適度買入&#34;，共識目標價格為$32.64。</p>
<p><strong>查看我們對 AARD 的最新分析</strong></p>
<h2>Aardvark Therapeutics 股價上漲 12.0%</h2>
<p>該公司的市值為 2.7539 億美元，市盈率為-5.97。該股票的 50 日移動平均價格為$13.76，200 日移動平均價格為$12.19。</p>
<p>Aardvark Therapeutics (NASDAQ:AARD - 獲取免費報告) 最近於 11 月 13 日發佈了季度財報。該公司報告季度每股收益為 ($0.75)，超出分析師的共識預期 ($0.82) $0.07。</p>
<h2>內部人士活動</h2>
<p>在其他 Aardvark Therapeutics 的新聞中，首席執行官 Tien-Li Lee 於 12 月 11 日以每股平均價格$14.48 購買了 7,000 股該公司的股票，總價值為$101,360.00。收購後，首席執行官直接持有該公司 1,551,613 股股票，價值約為$22,467,356.24。這筆交易代表其持股比例增加了 0.45%。該交易已在向證券交易委員會的法律文件中披露，文件可通過此鏈接訪問。此外，首席財務官 Nelson Sun 於 12 月 11 日以每股平均價格$14.40 購買了 3,000 股該公司的股票，總交易額為$43,200.00。交易後，首席財務官持有該公司 108,484 股股票，價值約為$1,562,169.60。這代表其持股比例增加了 2.84%。該購買的 SEC 文件提供了更多信息。</p>
<h2>機構投資者對 Aardvark Therapeutics 的看法</h2>
<p>幾家機構投資者最近對 AARD 的持倉進行了調整。Two Sigma Investments LP 在第三季度收購了 Aardvark Therapeutics 的新股份，價值$845,000。Bridgeway Capital Management LLC 在第三季度購買了 Aardvark Therapeutics 的新股份，價值約$292,000。瑞銀集團在第三季度將其在 Aardvark Therapeutics 的股份增加了 5.4%。瑞銀集團目前擁有 54,728 股該公司的股票，價值$727,000，在上個季度又購買了 2,804 股。法國巴黎銀行金融市場在第三季度將其在 Aardvark Therapeutics 的股份增加了 59.3%。法國巴黎銀行金融市場目前擁有 56,546 股該公司的股票，價值$751,000，在上個季度又購買了 21,052 股。最後，美國銀行在第二季度將其在 Aardvark Therapeutics 的持股增加了 72.9%。美國銀行目前擁有 7,989 股該公司的股票，價值$108,000，在此期間又購買了 3,369 股。</p>
<h2>Aardvark Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Aardvark Therapeutics, Inc 是一家位於馬薩諸塞州劍橋的臨牀階段生物製藥公司，專注於小分子調節劑的發現和開發，這些調節劑作用於視黃酸受體相關孤兒受體伽馬 (RORγ)。RORγ 在 T 輔助 17 (Th17) 細胞分化和炎症過程中發揮核心作用。通過靶向這一轉錄因子，Aardvark 旨在解決一系列自身免疫和免疫介導的疾病。</p>
<p>該公司的主要項目包括選擇性 RORγ 反向激動劑，旨在抑制在銀屑病、炎症性腸病和其他慢性炎症疾病等情況下由 Th17 驅動的病理反應。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Aardvark Therapeutics</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>~$1.5T SpaceX IPO：首次公開募股機會</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>在東部時間上午 9:30 到 10:45 之間進行交易</li>
<li>何時購買黃金（從數學角度）</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Aardvark Therapeutics 嗎？</h2>
<p>在考慮 Aardvark Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Aardvark Therapeutics 並不在名單上。</p>
<p>雖然 Aardvark Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AARD

<p>Aardvark Therapeutics (NASDAQ:AARD) 的股價上漲了 12%，達到 12.65 美元，市值為 2.7539 億美元。分析師給予的共識評級為 “適度買入”，目標價為 32.64 美元。最近的內部交易包括首席執行官 Tien-Li Lee 購買了 7,000 股，首席財務官 Nelson Sun 購買了 3,000 股。機構投資者也增加了對公司的持股。Aardvark 專注於開發針對自身免疫疾病的小分子調節劑，其主要項目針對 Th17 驅動的疾病</p>

<p>Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report)'s share price rose 12% on Friday . The stock traded as high as $13.03 and last traded at $12.65. Approximately 152,066 shares changed hands during trading, a decline of 18% from the average daily volume of 186,140 shares. The stock had previously closed at $11.29.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc. (NASDAQ:AARD - 獲取免費報告) 的股價在週五上漲了 12%。該股票最高交易價格為$13.03，最後交易價格為$12.65。在交易過程中，約有 152,066 股易手，較平均每日交易量 186,140 股下降了 18%。該股票之前的收盤價為$11.29。</p>
</div><p>Get <strong>Aardvark Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aardvark Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>AARD has been the subject of a number of research analyst reports. Raymond James Financial reiterated a &#34;strong-buy&#34; rating and set a $47.00 price target on shares of Aardvark Therapeutics in a report on Monday, January 12th. B. Riley Financial started coverage on Aardvark Therapeutics in a research note on Wednesday, January 28th. They set a &#34;buy&#34; rating and a $32.00 target price for the company. Cantor Fitzgerald reissued an &#34;overweight&#34; rating on shares of Aardvark Therapeutics in a report on Friday, November 14th. William Blair started coverage on Aardvark Therapeutics in a report on Friday, December 12th. They set an &#34;outperform&#34; rating for the company. Finally, BTIG Research initiated coverage on shares of Aardvark Therapeutics in a research report on Friday, November 7th. They set a &#34;buy&#34; rating and a $26.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Aardvark Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $32.64.</p>
<div class="lb-trans"><p>AARD 已成為多份研究分析師報告的主題。Raymond James Financial 在 1 月 12 日的報告中重申了對 Aardvark Therapeutics 的 &#34;強力買入&#34; 評級，並設定了$47.00 的目標價格。B. Riley Financial 在 1 月 28 日的研究報告中開始覆蓋 Aardvark Therapeutics，並設定了 &#34;買入&#34; 評級和$32.00 的目標價格。Cantor Fitzgerald 在 11 月 14 日的報告中重新發布了對 Aardvark Therapeutics 的 &#34;增持&#34; 評級。William Blair 在 12 月 12 日的報告中開始覆蓋 Aardvark Therapeutics，併為該公司設定了 &#34;跑贏大盤&#34; 評級。最後，BTIG Research 在 11 月 7 日的研究報告中開始覆蓋 Aardvark Therapeutics，並設定了 &#34;買入&#34; 評級和$26.00 的目標價格。一位分析師給予該股票 &#34;強力買入&#34; 評級，十一位給予 &#34;買入&#34; 評級，一位給予 &#34;賣出&#34; 評級。根據 MarketBeat.com 的數據，Aardvark Therapeutics 目前的共識評級為 &#34;適度買入&#34;，共識目標價格為$32.64。</p>
</div><p><strong>Check Out Our Latest Analysis on AARD</strong></p>
<div class="lb-trans"><p><strong>查看我們對 AARD 的最新分析</strong></p>
</div><h2>Aardvark Therapeutics Stock Up 12.0%</h2>
<div class="lb-trans"><h2>Aardvark Therapeutics 股價上漲 12.0%</h2>
</div><p>The company has a market cap of $275.39 million and a P/E ratio of -5.97. The stock has a 50 day moving average price of $13.76 and a two-hundred day moving average price of $12.19.</p>
<div class="lb-trans"><p>該公司的市值為 2.7539 億美元，市盈率為-5.97。該股票的 50 日移動平均價格為$13.76，200 日移動平均價格為$12.19。</p>
</div><p>Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.75) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.07.</p>
<div class="lb-trans"><p>Aardvark Therapeutics (NASDAQ:AARD - 獲取免費報告) 最近於 11 月 13 日發佈了季度財報。該公司報告季度每股收益為 ($0.75)，超出分析師的共識預期 ($0.82) $0.07。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部人士活動</h2>
</div><p>In other Aardvark Therapeutics news, CEO Tien-Li Lee acquired 7,000 shares of the business's stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $14.48 per share, with a total value of $101,360.00. Following the acquisition, the chief executive officer directly owned 1,551,613 shares of the company's stock, valued at approximately $22,467,356.24. This trade represents a 0.45% increase in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, CFO Nelson Sun bought 3,000 shares of the firm's stock in a transaction on Thursday, December 11th. The shares were acquired at an average price of $14.40 per share, for a total transaction of $43,200.00. Following the transaction, the chief financial officer owned 108,484 shares in the company, valued at approximately $1,562,169.60. This represents a 2.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.</p>
<div class="lb-trans"><p>在其他 Aardvark Therapeutics 的新聞中，首席執行官 Tien-Li Lee 於 12 月 11 日以每股平均價格$14.48 購買了 7,000 股該公司的股票，總價值為$101,360.00。收購後，首席執行官直接持有該公司 1,551,613 股股票，價值約為$22,467,356.24。這筆交易代表其持股比例增加了 0.45%。該交易已在向證券交易委員會的法律文件中披露，文件可通過此鏈接訪問。此外，首席財務官 Nelson Sun 於 12 月 11 日以每股平均價格$14.40 購買了 3,000 股該公司的股票，總交易額為$43,200.00。交易後，首席財務官持有該公司 108,484 股股票，價值約為$1,562,169.60。這代表其持股比例增加了 2.84%。該購買的 SEC 文件提供了更多信息。</p>
</div><h2>Institutional Investors Weigh In On Aardvark Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Aardvark Therapeutics 的看法</h2>
</div><p>Several institutional investors have recently made changes to their positions in AARD. Two Sigma Investments LP acquired a new stake in shares of Aardvark Therapeutics during the 3rd quarter worth $845,000. Bridgeway Capital Management LLC bought a new stake in Aardvark Therapeutics during the third quarter worth about $292,000. UBS Group AG grew its stake in Aardvark Therapeutics by 5.4% during the third quarter. UBS Group AG now owns 54,728 shares of the company's stock worth $727,000 after buying an additional 2,804 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Aardvark Therapeutics by 59.3% during the third quarter. BNP Paribas Financial Markets now owns 56,546 shares of the company's stock worth $751,000 after buying an additional 21,052 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Aardvark Therapeutics by 72.9% in the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock valued at $108,000 after buying an additional 3,369 shares during the period.</p>
<div class="lb-trans"><p>幾家機構投資者最近對 AARD 的持倉進行了調整。Two Sigma Investments LP 在第三季度收購了 Aardvark Therapeutics 的新股份，價值$845,000。Bridgeway Capital Management LLC 在第三季度購買了 Aardvark Therapeutics 的新股份，價值約$292,000。瑞銀集團在第三季度將其在 Aardvark Therapeutics 的股份增加了 5.4%。瑞銀集團目前擁有 54,728 股該公司的股票，價值$727,000，在上個季度又購買了 2,804 股。法國巴黎銀行金融市場在第三季度將其在 Aardvark Therapeutics 的股份增加了 59.3%。法國巴黎銀行金融市場目前擁有 56,546 股該公司的股票，價值$751,000，在上個季度又購買了 21,052 股。最後，美國銀行在第二季度將其在 Aardvark Therapeutics 的持股增加了 72.9%。美國銀行目前擁有 7,989 股該公司的股票，價值$108,000，在此期間又購買了 3,369 股。</p>
</div><h2>Aardvark Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Aardvark Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc 是一家位於馬薩諸塞州劍橋的臨牀階段生物製藥公司，專注於小分子調節劑的發現和開發，這些調節劑作用於視黃酸受體相關孤兒受體伽馬 (RORγ)。RORγ 在 T 輔助 17 (Th17) 細胞分化和炎症過程中發揮核心作用。通過靶向這一轉錄因子，Aardvark 旨在解決一系列自身免疫和免疫介導的疾病。</p>
</div><p>The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.</p>
<div class="lb-trans"><p>該公司的主要項目包括選擇性 RORγ 反向激動劑，旨在抑制在銀屑病、炎症性腸病和其他慢性炎症疾病等情況下由 Th17 驅動的病理反應。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Aardvark Therapeutics</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Trade this between 9:30 and 10:45 am EST</li>
<li>When to buy gold (mathematically)</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Aardvark Therapeutics</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>~$1.5T SpaceX IPO：首次公開募股機會</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>在東部時間上午 9:30 到 10:45 之間進行交易</li>
<li>何時購買黃金（從數學角度）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aardvark Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Aardvark Therapeutics 嗎？</h2>
</div><p>Before you consider Aardvark Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Aardvark Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Aardvark Therapeutics 並不在名單上。</p>
</div><p>While Aardvark Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Aardvark Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Aardvark Therapeutics（NASDAQ:AARD）股價上漲 12% - 現在是買入的好時機嗎？